IDBS ELN Powers World Class Preclinical Research at the UCT
News Jun 19, 2012
IDBS has announced that the University of Cape Town (UCT) Drug Discovery and Development Centre, H3-D (http://www.h3-d.uct.ac.za/), is using the BioBook Electronic Laboratory Notebook (ELN) to store, manage and analyze its Drug Metabolism and Pharmacokinetic (DMPK) data.
Aligning itself with international standards in drug discovery, H3-D benefits from BioBook’s ability to consolidate assay results in one place, improving workflow and accelerating preclinical research.
“BioBook helps us undertake world class research from right here in South Africa. It is an exciting step for us as we are not only working faster but we are doing so without compromising on quality. Our confidence in our data continues to grow every day,” said Dr Nyaradzo T.L Chigorimbo-Tsikiwa, a postdoctoral fellow within H3-D.
Chigorimbo-Tsikiwa continued, “Having worked with BioBook previously, I’m confident in its abilities to provide us with the efficiency and traceability that we require in our fast moving environment.”
BioBook is currently being rolled out across H3-D. Users are able to track research projects and manage the large volumes of data associated with individual assays.
Analysis is completed within the system rather than relying on Microsoft Excel for data handling.
Working in this efficient way minimizes the risk of human error and enables H3-D to advance it’s drug discovery on a global scale with conviction in its research findings.
Neil Kipling, CEO and Founder of IDBS said, “The world’s leading academic institutions are now taking advantage of industrial informatics platforms like BioBook. Our ELN significantly improves workflow and boosts research productivity by up to 30%. It also makes collaboration easier and enables better decision making. This new relationship with UCT demonstrates our commitment to providing global academia with modern informatics technologies which can revolutionize academic R&D.”
BioBook is a flexible, automated solution which dramatically reduces time to market in late stage discovery, pharmacology and preclinical R&D.
It integrates with legacy data software such as laboratory information management systems (LIMS) and combines data imported from laboratory instruments to keep all research in one secure environment.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018